Holen Sie sich die Stockscreener-App
2.8461
0.91%
0.0261
Schlusskurs vom Vortag:
$2.82
Offen:
$2.83
24-Stunden-Volumen:
1.26M
Relative Volume:
0.62
Marktkapitalisierung:
$277.61M
Einnahmen:
$35.95M
Nettoeinkommen (Verlust:
$-104.99M
KGV:
-2.0978
EPS:
-1.3567
Netto-Cashflow:
$-99.30M
1W Leistung:
+21.10%
1M Leistung:
-6.39%
6M Leistung:
+24.82%
1J Leistung:
+117.24%
1-Tages-Spanne:
$2.82
$3.02
1-Wochen-Bereich:
$2.41
$3.02
52-Wochen-Spanne:
$1.085
$3.82
C 4 Therapeutics Inc Stock (CCCC) Company Profile
Firmenname
C 4 Therapeutics Inc
Sektor
Branche
Telefon
(617) 231-0700
Adresse
490 ARSENAL WAY, WATERTOWN
Compare CCCC vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.845 | 275.17M | 35.95M | -104.99M | -99.30M | -1.3567 |
VRTX
Vertex Pharmaceuticals Inc
|
433.58 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.40 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.74 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Eingeleitet | TD Cowen | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-15 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2024-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Equal-Weight |
| 2024-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-12-13 | Hochstufung | Stifel | Hold → Buy |
| 2023-02-24 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-04-28 | Eingeleitet | Credit Suisse | Underperform |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-10 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-11-23 | Eingeleitet | BofA Securities | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-30 | Eingeleitet | Stifel | Hold |
| 2021-06-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-10-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-10-27 | Eingeleitet | Jefferies | Buy |
Alle ansehen
C 4 Therapeutics Inc Aktie (CCCC) Neueste Nachrichten
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
Analysts see significant upside in C4 Therapeutics (CCCC) stock - MSN
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Xilio Therapeutics gives 2 new hires stock options at $8.48 a share - Stock Titan
13 new Intellia employees get 67,150 stock units over 3 years - Stock Titan
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Director at C4 Therapeutics (NASDAQ: CCCC) granted 4,259 shares - Stock Titan
Director at C4 Therapeutics (NASDAQ: CCCC) takes stock pay - Stock Titan
New Bicara hire gets stock option for 44,175 shares at $20.50 - Stock Titan
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
Candel Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics reports new employee inducement award under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - bitget.com
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
CCCC Stock Price, Quote & Chart | C4 THERAPEUTICS INC (NASDAQ:CCCC) - ChartMill
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - globenewswire.com
Two new hires get 600,000 Plus Therapeutics stock awards - Stock Titan
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Is C4 Therapeutics (CCCC) stock outpacing its medical peers this year? - MSN
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update - MarketBeat
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? - finance.yahoo.com
C4 Therapeutics, Inc. advances pipeline as SVP Shagha Russell drives cemsidomide toward regulatory studies - Traders Union
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab for Relapsed/Refractory Multiple Myeloma - Investing News Network
C4 Therapeutics begins trial of cemsidomide with elranatamab - Investing.com
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma - The Manila Times
C4 Therapeutics Announces First Patient Dosed in Phase 1b - globenewswire.com
Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock - Insider Monkey
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma - bitget.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aug Shorts: Is C4 Therapeutics Inc currently under institutional pressureGap Down & Expert Approved Momentum Ideas - baoquankhu1.vn
New Zevra finance chief gets a 300,000-share stock option - Stock Titan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
Mineralys Therapeutics reports inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)March 13, 2026 - BioSpace
C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab - MarketBeat
Are you looking for a top momentum pick? Why C4 Therapeutics, Inc. (CCCC) is a great choice - MSN
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
18 new PTC Therapeutics hires receive stock options, RSUs - Stock Titan
Finanzdaten der C 4 Therapeutics Inc-Aktie (CCCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
C 4 Therapeutics Inc-Aktie (CCCC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| REYNO LEONARD | Chief Medical Officer |
Jan 16 '26 |
Sale |
2.22 |
10,000 |
22,200 |
156,382 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):